Skip to main content

Nasdaq IPOs

Payment processor Shift4 Payments sets terms for $300 million IPO

6 years 3 months ago
Shift4 Payments, which provides secure payment processing solutions, announced terms for its IPO on Monday. The company plans to raise an additional $100 million through a private placement to Rook Holdings, an affiliate of its founder. The Allentown, PA-based company plans
Renaissance Capital

US IPO Weekly Recap: 5 IPOs launch during the 4-day week

6 years 4 months ago
Just one SPAC priced in the shortened holiday week, but the IPO market still saw plenty of other activity. Five companies joined the IPO calendar, three company submitted initial filings, and another disclosed updated financials. On Tuesday, record label giant Warner Music (WMG)
Renaissance Capital

Phase 1 biotech Forma Therapeutics files for a $150 million IPO

6 years 4 months ago
Forma Therapeutics, a Phase 1 biotech company developing therapies for hematologic diseases and cancers, filed on Friday with the SEC to raise up to $150 million in an initial public offering.  The company's lead candidate, FT-4202, is a once-a day oral treatment for si
Renaissance Capital

GenScript spin-off Legend Biotech sets terms for $350 million IPO

6 years 4 months ago
Legend Biotech, a clinical stage CAR-T immuno-oncology biotech being spun out of GenScript, announced terms for its IPO on Friday. The company plans to raise an additional $12 million in a concurrent private placement to GenScript. The Somerset, NJ-based company plans to rai
Renaissance Capital

Molecular diagnostics provider Progenity files for a $100 million IPO

6 years 4 months ago
Progenity, which provides in vitro molecular diagnostic products for a variety of indications, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Progenity's current suite of products includes chromosomal and monogenic prenatal tests,
Renaissance Capital

Fibrosis biotech Pliant Therapeutics sets terms for $90 million IPO

6 years 4 months ago
Pliant Therapeutics, a Phase 2 biotech developing therapies for the treatment of fibrosis, announced terms for its IPO on Tuesday. The company plans to raise an additional $10 million through a concurrent private placement to Novartis. The South San Francisco, CA-based compa
Renaissance Capital
Checked
23 minutes 39 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed